CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

By afschroeder • April 28, 2026

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.

Tags: breast cancer, bullous dermatitis, CDK4/6 inhibitors, Hematology/Oncology, Publications, rash, topical corticosteroids

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]

mGEM: multigraph estimation models for pattern analysis

Landeros A, Krishnan D, Lange K, Sehl M. mGEM: multigraph estimation models for pattern analysis. BMC Bioinformatics. 2026 May 20. doi: 10.1186/s12859-026-06467-3. Epub ahead of[...]